Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors

J Neurosci. 2002 Feb 1;22(3):1054-62. doi: 10.1523/JNEUROSCI.22-03-01054.2002.

Abstract

To investigate the role of A(2A) adenosine receptors in adaptive responses to chronic intermittent dopamine receptor stimulation, we compared the behavioral sensitization elicited by repeated l-DOPA treatment in hemiparkinsonian wild-type (WT) and A(2A) adenosine receptor knock-out (A(2A) KO) mice. Although the unilateral nigrostriatal lesion produced by intrastriatal injection of 6-hydroxydopamine was indistinguishable between WT and A(2A) KO mice, they developed strikingly different patterns of behavioral sensitization after daily treatment with low doses of l-DOPA for 3 weeks. WT mice initially displayed modest contralateral rotational responses and then developed progressively greater responses that reached a maximum within 1 week and persisted for the duration of the treatment. In contrast, any rotational behavioral sensitization in A(2A) KO mice was transient and completely reversed within 2 weeks. Similarly, the time to reach the peak rotation was progressively shortened in WT mice but remained unchanged in A(2A) KO mice. Furthermore, daily l-DOPA treatment produced gradually sensitized grooming in WT mice but failed to induce any sensitized grooming in A(2A) KO mice. Finally, repeated l-DOPA treatment reversed the 6-OHDA-induced reduction of striatal dynorphin mRNA in WT but not A(2A) KO mice, raising the possibility that the A(2A) receptor may contribute to l-DOPA-induced behavioral sensitization by facilitating adaptations within the dynorphin-expressing striatonigral pathway. Together these results demonstrate that the A(2A) receptor plays a critical role in the development and particularly the persistence of behavioral sensitization to repeated l-DOPA treatment. Furthermore, they raise the possibility that the maladaptive dyskinetic responses to chronic l-DOPA treatment in Parkinson's disease may be attenuated by A(2A) receptor inactivation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Adaptation, Physiological / physiology
  • Animals
  • Autoradiography
  • Behavior, Animal / drug effects*
  • Corpus Striatum / chemistry
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Corpus Striatum / pathology
  • Dopamine / metabolism
  • Dopamine Plasma Membrane Transport Proteins
  • Drug Administration Schedule
  • Dynorphins / genetics
  • Dynorphins / metabolism
  • Female
  • Levodopa / administration & dosage*
  • Male
  • Membrane Glycoproteins*
  • Membrane Transport Proteins / metabolism
  • Mice
  • Mice, Knockout
  • Motor Activity / drug effects
  • Nerve Tissue Proteins*
  • Oxidopamine
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / metabolism*
  • Parkinson Disease, Secondary / pathology
  • RNA, Messenger / metabolism
  • Receptor, Adenosine A2A
  • Receptors, Purinergic P1 / deficiency
  • Receptors, Purinergic P1 / genetics
  • Receptors, Purinergic P1 / metabolism*
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology

Substances

  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • RNA, Messenger
  • Receptor, Adenosine A2A
  • Receptors, Purinergic P1
  • 3,4-Dihydroxyphenylacetic Acid
  • Levodopa
  • Dynorphins
  • Oxidopamine
  • Dopamine